GLP‑1s and Your Brain: Depression, Cravings, and "Ozempic Personality"

The most consistent psychiatric signal from GLP-1s is craving reduction, and it generalizes beyond eating.

In a randomized clinical trial published in JAMA Psychiatry (2025), adults with alcohol use disorder received low-dose weekly semaglutide or placebo for nine weeks. The semaglutide group showed reduced alcohol cravings, fewer drinks per drinking day, and greater reductions in heavy drinking days — with effect sizes the authors noted appeared potentially larger than existing approved AUD medications, at the lowest clinical doses.1 A larger 2026 randomized trial in The Lancet in patients with alcohol use disorder and obesity has since added weight to the finding.23 As a bonus signal, smokers in the JAMA trial also cut their cigarettes per day significantly versus placebo.1

Why would a gut-hormone drug do this? GLP-1 receptors sit in the brain's reward circuitry.5 The drugs appear to turn down anticipatory reward — the "wanting" — across targets: food, alcohol, nicotine, possibly gambling. Clinicians hear the same phrase from patients over and over: "the noise stopped." That pattern now has a formal definition and a measurement, which we cover in what food noise is.7

Status: promising but off-label. No GLP-1 is approved for addiction. If you have a substance use problem, this is a conversation to have with a physician — not a reason to self-prescribe a weight-loss drug.

This question is settled about as well as drug-safety questions get. After reviewing 91 placebo-controlled trials covering 107,910 patients, plus a cohort study of over 2.2 million users, the FDA concluded in January 2026 that GLP-1s show no increased risk of suicidal ideation or behavior — and formally requested that the warning be removed from the labels of Wegovy, Zepbound, and Saxenda.4

Here's the bigger idea behind these findings, and it's changing how forward-thinking clinics treat mood disorders: mental health is deeply biological — and some of what gets diagnosed as psychiatric may be metabolic.

Two patients present with identical anxiety. One has chronic sleep disruption and dysregulated hormones; the other has insulin resistance. Under the standard symptom-checklist model, both get the same prescription. Clinics at the frontier of "metabolic psychiatry" now run full lab panels first — glucose regulation, hormones, micronutrients, inflammation — and treat what they find. Nikita Tsimmer, whose NYC clinic Fountain Health runs labs on every incoming mental-health patient, described the model at DLD Health: "mental health is actually deeply biological."8 His clinic is among those trialing low-dose GLP-1s off-label for mental-health indications and collecting data for publication.8

For patients labeled "treatment-resistant" after years of medication cycles, this reframe can be profound. As Tsimmer puts it, the question shifts from "what's wrong with me?" to "why hasn't anyone looked at this sooner?"8 If you've done everything right — therapy, medication, time — and nothing moved, a metabolic workup is a reasonable next conversation to have with your doctor.

Status: biologically plausible, supported by observational data linking insulin resistance and depression, but the interventional evidence (does treating metabolism fix mood?) is still being built. Watch this space; we will cover the trials as they publish.

Now the other side of the ledger. A subset of GLP-1 users report emotional blunting: less joy, less motivation, life feeling "meh." The press named it "Ozempic personality" in 2026, and the reports are consistent enough to take seriously.6

The leading hypothesis is the same mechanism running too hot: a drug that dampens reward circuitry to silence food noise may, in some people at some doses, dampen reward, period.56 The anticipation of dinner with friends, the pull of a hobby, ambition itself — all run on the same dopaminergic wiring as cravings.

No controlled trial has yet quantified how common this is, and the population-level data (see the FDA review above) is reassuring.4 But individually, the fix is often straightforward: dose reduction, switching agents, or discontinuing typically reverses it.6 The mistake is not reporting it — if you feel flattened on a GLP-1, tell your prescriber. It is not in your head, and it is usually adjustable.

GLP-1s are the strongest evidence yet that the line between metabolic and mental health was always artificial. They reliably quiet cravings, they don't raise suicide risk, they may help mood for some — and they flatten it for others. Which effect you get depends on your biology, your dose, and the quality of care around the prescription.

That last part is the real takeaway: these medications reward a system — labs, monitoring, lifestyle foundations, an attentive clinician — and punish a transaction. Our programme ranking grades providers on what they include beyond the prescription.

Does Ozempic cause depression? Large-scale evidence says no — the FDA found no increased risk of suicidality or psychiatric adverse events across 91 trials and requested warning-label removal in January 2026.4 A minority of users do report emotional blunting or low motivation, which typically resolves with dose adjustment.6

Does Ozempic help with alcohol cravings? In randomized trials, low-dose semaglutide reduced alcohol cravings, drinks per drinking day, and heavy drinking days versus placebo.12 It is not approved for alcohol use disorder; use for this purpose is off-label and should involve a physician.

Can GLP-1s treat depression? Not established. The metabolic-psychiatry hypothesis is promising and under active study, but no GLP-1 is approved for any psychiatric indication.8

What is "Ozempic personality"? A colloquial term for emotional blunting some users experience on GLP-1s — reduced excitement, motivation, or pleasure. Mechanism is hypothesized (reward-circuit dampening), prevalence is unknown, and it is generally reversible with dose changes.6

This article is for information only and is not medical advice. If you're struggling with your mental health or substance use, talk to a licensed clinician. In the US, you can call or text 988 for immediate support.